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Blinatumomab vs historical standard therapy of adult relapsed/
refractory acute lymphoblastic leukemia
N Gökbuget1, M Kelsh2, V Chia2, A Advani3, R Bassan4, H Dombret5, M Doubek6, AK Fielding7, S Giebel8, V Haddad9, D Hoelzer1,
C Holland10, N Ifrah11, A Katz2, T Maniar12, G Martinelli13, M Morgades14, S O’Brien15, J-M Ribera14, JM Rowe16, A Stein17, M Topp18,
M Wadleigh19 and H Kantarjian15
We compared outcomes from a single-arm study of blinatumomab in adult patients with B-precursor Ph-negative relapsed/
refractory acute lymphoblastic leukemia (R/R ALL) with a historical data set from Europe and the United States. Estimates of
complete remission (CR) and overall survival (OS) were weighted by the frequency distribution of prognostic factors in the
blinatumomab trial. Outcomes were also compared between the trial and historical data using propensity score methods. The
historical cohort included 694 patients with CR data and 1112 patients with OS data compared with 189 patients with CR and
survival data in the blinatumomab trial. The weighted analysis revealed a CR rate of 24% (95% CI: 20–27%) and a median OS of
3.3 months (95% CI: 2.8–3.6) in the historical cohort compared with a CR/CRh rate of 43% (95% CI: 36–50%) and a median OS of
6.1 months (95% CI: 4.2–7.5) in the blinatumomab trial. Propensity score analysis estimated increased odds of CR/CRh (OR= 2.68,
95% CI: 1.67–4.31) and improved OS (HR= 0.536, 95% CI: 0.394–0.730) with blinatumomab. The analysis demonstrates the
application of different study designs and statistical methods to compare novel therapies for R/R ALL with historical data.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is a rare disease with age-
standardized rates ranging from approximately 1 to 2 per 100 000
across various geographies.1 Frontline treatments developed for
adult patients are often adapted from pediatric approaches and
have improved disease prognosis; however, if relapse occurs
outcomes are very poor.2 In relapsed or refractory (R/R) ALL,
complete remission (CR) after salvage treatment was reported in
18–45% of patients and median overall survival (OS) times range
from 2 to 8 months.3–7 Reported prognostic factors for worse
outcomes among adult R/R ALL patients include older age, later
line of salvage treatment, shorter time to relapse from initial
achievement of CR, and relapse after receiving allogeneic
hematopoietic stem cell transplant (alloHSCT).3,5,7
Blinatumomab is a BiTE antibody construct that redirects CD3-
expressing T-cells to CD19-expressing leukemic cells to induce
T-cell activation, proliferation and serial tumor-cell lysis.8 Blinatu-
momab was recently approved by the Food and Drug Adminis-
tration for patients with R/R ALL largely on the basis of a phase 2
single-arm study (MT103-211) in 189 adult patients.9,10 The study
population was comprised of patients with poor prognostic factors,
including early ﬁrst relapse and later lines of salvage therapy,
making a direct comparison with published data difﬁcult. After
blinatumomab treatment, 43% of patients achieved a response (CR
or CR with partial hematological recovery of peripheral blood counts
(CRh)) and the median (OS) was 6.1 months.
There are a number of potential approaches for evaluating the
relative beneﬁts and risks of a new therapy that uses direct
evidence only from single-arm or uncontrolled studies. The
strengths and weaknesses of these approaches are summarized
in Supplementary Table S1, and include literature review, meta-
analysis, evaluation of clinical evidence from a large treating
center and pooled analysis of individual patient-level data
collected from a number of sites.
Regulatory agencies recognize the option of using external
historical controls to demonstrate new treatment efﬁcacy for
accelerated approval when a disease is rare, has no satisfactory
treatment and the new treatment appears very promising based
on preliminary data.11,12 This paper will describe the approach taken
to evaluate results of the single-arm clinical trial for the approval of
blinatumomab in the USA and Europe.9,13,14 To provide context for
the clinical trial, we conducted a ‘historical comparator’ study to
evaluate CR and OS with standard of care salvage chemotherapy in
adults with Ph-negative, B-precursor R/R ALL.
The historical data set was pooled from European national study
groups and large individual sites from Europe and the United
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States.13–15 Two analytical approaches were used. The ﬁrst was a
weighted analysis, whereby outcomes from the historical data set
were weighted according to the frequency distribution of
predetermined prognostic baseline factors in the blinatumomab
clinical trial population. The second was a propensity score
analysis, which created a better balance between historical and
blinatumomab-treated patients with respect to important baseline
factors, and enabled quantiﬁcation of differences in outcomes
between the two groups. Both methods allowed for more
accurate comparisons between historical and clinical trial data
than simple descriptive, subgroup or stratiﬁed analyses.
MATERIALS AND METHODS
Historical comparator study
Full details on the historical comparator study design and data collection
are described elsewhere.13–15 The key eligibility criteria were: (1) adult
patients with R/R Ph-negative B-precursor ALL, (2) age ⩾ 15 years at time of
initial diagnosis of ALL, (3) initial diagnosis of ALL in the year 1990 or later,
(4) no central nervous system involvement at relapse, (5) no isolated
extramedullary relapse and (6) no previous treatment with blinatumomab.
Anonymized patient data from six national study groups and ﬁve large
treatment centers (Supplementary Table S2) were forwarded to Amgen for
inclusion in the pooled analysis. The anonymized data were checked,
pooled and harmonized into a single data set containing predeﬁned
variables and outcomes of interest. All authors had full access to the data
they provided, and they reviewed and approved summaries of data from
their study group or center and the pooled data. Patients had provided
informed consent for the collection and use of their data for research
purposes in the original study databases. The ﬁnal protocol was approved
by the relevant institutional review boards if applicable, and was registered
at clinicaltrials.gov as NCT02003612.
Blinatumomab clinical trial patient population
Full details of the blinatumomab single-arm phase 2 study (MT103-211) are
described elsewhere.10 The clinical study population included adult (⩾18
years) patients with Ph-negative, B-precursor R/R ALL (ﬁrst relapse
⩽ 12 months of ﬁrst remission, relapse o12 months after alloHSCT, or
no response to or relapse after ﬁrst salvage therapy or beyond). This study
was conducted at sites across Europe and the United States and included 189
adult R/R ALL patients, enrolled over the period 2010–2014. Patients received
blinatumomab (9 μg/day for the ﬁrst 7 days and 28 μg/day thereafter) by
continuous intravenous infusion over 4 weeks every 6 weeks (up to ﬁve
cycles), and were followed for remission, survival and safety outcomes.
Patient selection from the historical data set
To enable closer comparison with patients from the blinatumomab clinical
trial, patients from the pooled historical database were further selected
based on key eligibility criteria of the blinatumomab trial: (1) age ⩾ 18
years at relapse and (2) relapsed within 12 months from initial diagnosis, or
relapsed after alloHSCT, or refractory to initial or subsequent treatments, or
in second or later relapse. Patients with a ﬁrst remission duration of
412 months and remaining in ﬁrst salvage without further relapse were
excluded, unless they had a relapse within 12 months of receiving
alloHSCT. In addition, patients for whom only palliative care was recorded
or had no veriﬁable record of salvage therapy were excluded. In patients
with information on several lines of salvage therapy, only the end points
for the latest available salvage therapy were selected for analysis. This
mimicked the likely time period when a patient would have entered the
blinatumomab study.
Outcome measures
The primary study outcome for the weighted analysis from the historical
data set was achievement of CR after salvage therapy as deﬁned by the
individual study groups.15 European sites usually deﬁned CR according to
standard criteria, that is, bone marrow blasts o5% and no peripheral blast
cells or extramedullary manifestations,7 and US study sites generally used
CR criteria as published for acute myeloid leukemia, involving the
complete recovery of peripheral counts.16 A secondary outcome was OS,
deﬁned as the time from the start of last salvage therapy to death from any
cause. The remission end point in the blinatumomab trial was CR (⩽5%
bone marrow blasts, platelets4100 000/μl, ANC41000/μl) and CRh (⩽5%
bone marrow blasts, platelets 450 000/μl, ANC 4500/μl), without
peripheral blasts or extramedullary disease. OS was calculated as time
from blinatumomab treatment initiation to death or date of last follow-up.
Statistical analysis
Weighted analysis. Summary estimates of study outcomes from the
historical data set were calculated by weighting the frequency distribution
of known prognostic factors in R/R ALL, according to standard
methods.17 Prognostic factors were deﬁned based on published data
and the availability of the respective parameters in both data sets, and
then used to deﬁne patient strata. Six mutually exclusive strata were
deﬁned by a combination of age, prior alloHSCT and line of salvage
treatment among patients with available CR or OS data.
For each of the six strata, the proportion of patients with a CR
was estimated along with an exact 95% conﬁdence interval (CI). The
proportions of patients with CR across strata were then pooled
into a combined estimate with each stratum weighted to the percen-
tage of patients observed in that stratum from the blinatumomab
trial. A 95% CI was estimated for the combined estimate via
bootstrapping.18
For OS, the Kaplan Meier (KM) median and KM proportions at 6 and
12 months were estimated. The 95% CI for the median within each stratum
was estimated.19 The 95% CI for the 6- and 12-month KM proportions
within each stratum was estimated using the method described in
Kalbﬂeisch and Prentice.20 A combined estimate and 95% CI were derived
using the stratum-weighted approach described above.
Sensitivity analyses were conducted to see if there were differences in
CR and OS over time. Time periods were deﬁned from 2000 onwards, from
2000 to 2004, and from 2005 onwards. Because sites contributed data over
varying time periods, and treatment practices at sites may inﬂuence
response and survival estimates, we also assessed CR and OS by time
period only in sites that had data across the entire study period—that is,
from 1990 to 2013.
Propensity score analysis. A propensity score analysis was used to balance
measured characteristics between patients in the blinatumomab clinical
trial and patients in the historical data set.21 Data from the clinical trial and
the historical data set were merged and candidate covariates were
selected based on published data regarding their prognostic impact, their
ability to discriminate between patients who were and were not
treated with blinatumomab, and their availability in both data sets. The
available covariates included: (1) age (years), (2) sex (male, female),
(3) duration between initial diagnosis and salvage therapy (months),
(4) region (USA, Europe), (5) prior HSCT (yes, no), (6) prior number of
salvage therapies (1, 2, 3 and 4+ (treated as a continuous variable)),
(7) primary refractory and in ﬁrst salvage (yes, no) and (8) refractory to last
salvage therapy (yes, no).
An estimated propensity score (i.e., the predicted probability of
participating in the blinatumomab clinical trial if it were being conducted
during the period of historical data) was assigned to each patient based on
the patient’s set of selected covariates.16,22 The balance of covariates
between patients in the blinatumomab clinical trial and patients in the
historical data set was determined both by regression modeling and by
calculation of standardized differences.
In the estimation of treatment effects, propensity scores were used to
adjust for differences between patients in the blinatumomab clinical
trial and patients in the historical data set using inverse probability of
treatment weighting (IPTW) methods.23,24 To address the potential of over-
inﬂuence of IPT weights among patients with very low probability of
participating in the blinatumomab clinical trial, stabilized IPTW (sIPTW)
methods were also used as well as trimmed IPTW and sIPTW values
whereby outlier values were truncated to maximum non-outlier values.25
CR and CR/CRh rates were analyzed using a logistic regression model with
a single treatment indicator covariate and propensity score-based weights
to adjust for differences between the blinatumomab trial patients and
those in the historical data set. The model’s coefﬁcient for the treatment
effect was used to obtain an odds ratio (OR) and a robust variance
estimation (applied using a generalized estimating equation26) was used to
construct 95% CIs to evaluate the difference in CR and CR/CRh rates
between patients in the blinatumomab clinical trial and patients in the
historical data set. Similarly, OS was analyzed via a Cox proportional
hazards model with a single treatment indicator covariate and using
propensity score-based IPTW or sIPTW weights to adjust for differences
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between the blinatumomab trial patients and patients in the historical data
set. A hazard ratio (HR) and 95% CI (using robust variance estimation) were
calculated to measure the risk of death among patients in the
blinatumomab clinical trial relative to patients in the historical data set.
RESULTS
Demographics and characteristics of the historical data set patient
population
Initially the pooled historical comparator database included 2373
patients with complete remission or survival data (Figure 1). As
described above, patients were excluded from the analyses if they
did not match the major eligibility criteria of the blinatumomab
trial. After further excluding patients with missing outcomes or
stratum data (age, treatment history), 694 patients were included
in the CR analyses and 1112 in the survival analysis (Figure 1). The
number of patients provided by collaborating study groups or
sites that met the inclusion criteria ranged from 15 to 233, with
1139 patients providing data for analysis of either CR or OS
(Supplementary Table S2).
Demographic characteristics were similar between patients with
remission or survival data available in the analysis from the
historical data set: a majority were male (approximately 60%); the
mean age was 37–39 years, with 45–47% younger than 35 years
old (Table 1). The ratio of European to US patients was higher in
the OS analysis set than the CR analysis set. This is because two of
the European sites provided only OS data. Most patients (64–67%)
in both analysis sets were initially diagnosed with ALL in the year
2000 or later. Other characteristics showed only slight differences
(Table 1).
The demographic and clinical characteristics of the blinatumo-
mab clinical trial population varied on several characteristics
compared with the historical data. There were proportionally
fewer patients who were in ﬁrst salvage, more patients who had a
previous HSCT and more patients who had received multiple
salvage treatments in the blinatumomab clinical trial (Table 1).
Weighted analysis
Complete remission in the historical comparator patient population.
The combined CR rate in the historical data set, weighted to the
distribution of patient characteristics in the blinatumomab trial,
was 24% (95% CI: 20–27%). In the blinatumomab trial a CR/CRh of
43% (95% CI: 36–50%) was observed. The proportion of patients
with CR in the blinatumomab trial was 33% (95% CI: 27–41%).10
Stratum-speciﬁc rates in the historical data ranged from 17 to
44%, with the lowest rates among patients in second or greater
salvage and the highest rates among younger patients in ﬁrst
salvage (Table 2). The weighted CR estimate in the historical data
was driven by the low CR in patients in second or greater salvage,
who accounted for approximately 50% of the blinatumomab
study population. CR rates decreased progressively with each line
of salvage therapy (Supplementary Table S3).
Sensitivity analyses were conducted in different time periods
(Supplementary Table S4). Compared with the overall population,
the CR rate was slightly higher in patients treated from the year
2000 onward (26%, 95% CI: 20–28%), and even higher for patients
treated from 2005 onward (30%, 95% CI: 22–37%). However, when
limiting analyses to only sites that provided data across the entire
time period (i.e., from 1990 to 2013), there was no difference
observed in CR rates from 1990 to 1999 (19%, 95% CI: 12–27%)
compared with rates from 2000 onward (19%, 95% CI: 12–25%).
Overall survival in the historical comparator patient population.
The combined median OS in the historical data set, weighted to
the distribution of patient characteristics in the blinatumomab
trial, was 3.3 months (95% CI 2.8–3.6 months) (Table 3 and
Supplementary Figure S1). The weighted 6-, 12- and 36-month
survival proportions were 30% (95% CI 27–34%), 15% (95% CI 8–
Figure 1. Historical database analysis cohort.
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19%) and 6% (95% CI 4–8%), respectively (Table 3). In comparison,
the median OS in the blinatumomab clinical trial was 6.1 months
(95% CI 4.2–7.5), and the 6- and 12-month survival proportions
were 50 and 28%, respectively, with data unavailable for
calculation of 36-month survival proportion (Table 3). Stratum-
speciﬁc median survival ranged from 2.2 to 5.7 months (Table 3).
Similar to the CR results, poor survival was observed among
patients who were in second or greater salvage and among older
patients (Table 3).
Sensitivity analyses for OS by time period showed that OS
increased over time, with a median survival of 3.8 months (95% CI:
3.3–4.3) for patients treated from the year 2000 onward and median
survival of 4.2 months (95% CI: 3.3–4.9) for patients treated from
2005 onward (Supplementary Table S4). When data were limited to
only sites that provided data across the entire time period, median
survival increased over time but was not greater than the overall
population: median OS was 2.4 months (95% CI: 1.8–2.8) from 1990
to 1999 and 3.2 months (95% CI: 2.7–3.7 months) from 2000 onward.
Table 1. Demographics and patient characteristics—historical comparator and clinical trial data
Historical data set Clinical trial data
Patients with CR data Patients with OS data Blinatumomab trial (MT103-211)
N= 694 N=1112 N=189a
Sex, n (%)
Male 421 (60.7) 644 (57.9) 119 (63%)
Female 273 (39.3) 468 (42.1) 70 (37%)
Mean (s.d.) age, years 38.8 (14.8) 37.4 (14.2) 41.1 (17.3)
Age group (years)
18–34 317 (45.6) 527 (47.4) 90 (48)
35–54 256 (36.9) 428 (38.5) 46 (24)
⩾ 55 80 (11.5) 115 (10.3) 53 (28)
⩾ 65 41 (5.9) 42 (3.8) 25 (13)
Disease status, n (%)
Primary refractory 16 (8.5)
In 1st salvage 61 (8.8) 56 (5.0) 4 (2.1)
In 2nd or greater salvage 50 (7.2) 61 (5.5) 12 (6.3)
Relapsed, with prior alloHSCT 64 (33.9)
In 1st salvage 44 (6.3) 130 (11.7) 9 (4.8)
In 2nd or greater salvage 45 (6.5) 57 (5.1) 55 (29.1)
Relapsed, without prior alloHSCT 109 (57.7)
In 1st salvage 245 (35.3) 543 (48.8) 25 (13.2)
In 2nd or greater salvage 249 (35.9) 265 (23.8) 84 (44.4)
Year of initial diagnosis, n (%)
1990 to 1999 246 (35.4) 364 (32.7) 0 (0)
2000 or later 448 (64.6) 748 (67.3) 189 (100)
Region, n (%)
Europe 393 (56.6) 811 (72.9) 95 (50)
USA 301 (43.4) 301 (27.1) 94 (50)
aNumbers by salvage treatment in disease status categories not totalling due to missing data for salvage history (need to verify).
Table 2. Stratiﬁed and weighted analysis results: comparison of historical data and blinatumomab clinical trial data: CR by strata and weighted to
blinatumomab clinical data
Stratum Deﬁnition Blinatumomab trial (MT103-211) Historical data set
Age Disease status N Stratum proportion (%) Number
with CR a
CR/CRh %
(95% CI)
N Stratum proportion (%) Number
with CR
CRsg %
(95% CI)
o35 Prior alloHSCTb 40 21.2 15 38 (23, 54) 48 6.9 14 29 (17, 44)
o35 In 1st salvagec 10 5.3 7 70 (35, 93) 119 17.1 52 44 (35, 53)
o35 In 2nd or greater salvagec 40 21.2 17 43 (27, 59) 150 21.6 27 18 (12, 25)
⩾ 35 Prior alloHSCTb 24 12.7 14 58 (37, 78) 41 5.9 11 27 (14, 43)
⩾ 35 In 1st salvagec 19 10.1 5 26 (9, 51) 187 26.9 57 30 (24, 38)
⩾ 35 In 2nd or greater salvagec 56 29.6 23 41 (28, 55) 149 21.5 25 17 (11, 24)
Combined weighted summary 189 100 81 43 (35, 50) 694 100 186 24 (20, 27)
aCR deﬁned as CR+CRh: includes patients with complete remission with full peripheral count recovery (CR, ⩽ 5% bone marrow blasts, platelets4100 000 cells
per μl, absolute neutrophil count 41000 cells per μl) and patients with complete remission and partial recovery (CRh, ⩽ 5% bone marrow blasts, platelets
450 000 cells per μl, absolute neutrophil count 4500 cells per μl). bAll patients with a history of alloHSCT. They could be in 1st, 2nd or greater salvage. cAll
patients without a history of alloHSCT.
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Propensity score analysis
Covariate balance. The balance in baseline covariates between
patients in the blinatumomab clinical study and the historical data
was assessed both before and after making adjustments for the
propensity score (Supplementary Table S5). Before adjustment,
signiﬁcant differences in six of eight covariates were observed
between the two groups of patients. Notably, the blinatumomab
patients were more heavily pre-treated than the historical patients
(average line of salvage therapy 2.36 vs 1.52, Po0.0001) and more
were refractory to their last line of salvage (52% vs 23%,
Po0.0001). Standardized differences were substantially reduced
after propensity score adjustment for nearly all of the available
covariates (reduction for 7 of 8 covariates). After adjustment there
were no signiﬁcant differences in any covariates between patient
groups except for region (more patients from Europe in the
historical data set). If important covariates or baseline factors were
not adequately balanced, then additional sensitivity analyses were
conducted adding those factors as additional covariates into the
logistic regression or Cox models. The additional variables were
added to the ‘adjusted’ models when the P-value for the factor
was o0.05, or when the standardized difference exceeded 0.10.
Generally, balance between the groups was considered to be
achieved without the need for further adjustment and the CR and
OS outcomes were analyzed.
Complete remission. The proportion of patients from the
historical data set achieving CR was compared with the proportion
of patients from the blinatumomab trial achieving CR/CRh. The
predicted proportions (95% CI) were higher in the blinatumomab
patients (49% (33–65%)) than in the historical patients (27% (23–
30%)) (Table 4). Figure 2a shows that the odds of achieving a CR
were more than doubled with blinatumomab treatment (sIPTW
OR=2.68, 95% CI: 1.67–4.31). These ﬁndings were also observed
across various analyses where subsets of the historical data
(patients diagnosed after 2000) were assessed (Supplementary
Figure S2).
Overall survival. Consistent with the weighted analyses, overall
survival was longer among blinatumomab patients (Supple-
mentary Figure S1). Survival proportions were higher in the
blinatumomab group than in the historical group after 6 months
(58% vs 33%) and 12 months (39% vs 17%) (Table 4). Figure 2b
shows that the hazard ratio from the standardized IPTW
comparison was 0.54 (95% CI: 0.40–0.73) with an upper bound
to the 95% CI below the reference value of 1.0. As with CR,
ﬁndings for survival were similar in subsets of patients diagnosed
after the year 2000 (Supplementary Figure S2).
DISCUSSION
In special cases when a disease is rare, prognosis is very poor, and
there are limited therapeutic options available, single-arm clinical
trials may be used as evidence for accelerated drug approvals.
Comprehensive evaluation of historical comparator or reference
data can provide an additional approach for putting the efﬁcacy of
a new therapy into perspective.11,12 In this study, we applied
different statistical methods and sensitivity analyses to evaluate
the clinical efﬁcacy of blinatumomab against historical data.
Outcomes in previously reported studies of adults with R/R ALL
are universally poor, but vary across different populations with
different disease characteristics. The overall pooled historical data
set (before selection based on blinatumomab study entry criteria)
included patients from these studies and showed signiﬁcant
differences in outcomes between different patient subgroups.15
For example, higher CR rates were observed in patients with a
longer time to ﬁrst relapse (⩾24 months, 65% vs o6 months,
34%), patients who were younger (15–17 years, 56% vs ⩾ 65 years,T
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26%) and patients in ﬁrst salvage (ﬁrst salvage, 40% vs third or
later salvage, 11%). This is highly relevant for the comparison of
different published patient cohorts with variable distribution of
these factors. Thus, the direct comparison of major covariates
(Supplementary Table S5) demonstrated that almost all of them
showed highly signiﬁcant differences between the historical data
set and the blinatumomab trial. These ﬁndings emphasize the
importance of using appropriate methods to adjust for differences
in critical prognostic factors when comparing speciﬁc clinical trial
results with historical data.
The blinatumomab clinical trial population enrolled patients
with particularly advanced disease characteristics, including those
with short time to ﬁrst relapse, prior HSCT and later lines of
salvage therapy.10 These patients represent a subgroup of an
already small patient population.1 In order to obtain reliable
historical estimates of CR and OS, it was necessary to assemble a
large historical data set representative of standard of care in
Europe and the USA. From this data set, we were able to select a
comparable population of patients to those in the blinatumomab
clinical trial.
The weighted analysis and propensity score analysis showed
consistently favorable results when comparing blinatumomab to
the historical comparator data. CR and median OS in patients
treated with blinatumomab were approximately double those in
the historical population, both overall and within most of the
different patient strata.
Concerns often raised regarding the use of historical compara-
tor data are the inﬂuence of potential biases related to selection,
misclassiﬁcation and confounding.12 The requirement of rigorous
eligibility criteria in the blinatumomab clinical study—such as
Eastern Cooperative Oncology Group status of two or lower and
absence of abnormal lab values during screening—may increase
the chance of better outcomes in the clinical study than the
historical data. While it may be possible to use unadjusted
historical data when patient populations are sufﬁciently similar,27
the disproportionate number of advanced-stage patients in the
blinatumomab trial required methods applied to individual-level
data to minimize bias. Selection bias was minimized by use of
stringent inclusion criteria into the historical data set and by
weighting or adjusting for known prognostic factors. In addition,
the historical data set represented adult R/R patients who received
standard of care (excluding palliative care patients where
possible), without any restrictions to any patient subgroups.
Residual confounding may still remain and be difﬁcult to control
for, particularly in data sets where differences in important
prognostic factors are unknown or not measured in one data set.
In this study, nearly all known important prognostic factors were
adjusted for in the weighted or propensity score analyses. Missing
data on key covariates lead to exclusion of some records from the
analyses (Figure 1), which may theoretically bias the overall results.
However, our examination of records with missing covariates did
not identify signiﬁcant differences by patient demographic
characteristics compared with patients who had complete data
(data not shown). Misclassiﬁcation bias was limited by harmoniza-
tion of patient-level data in the pooled analysis, which employed
common data deﬁnitions for disease classiﬁcation and outcomes
characterization.
Although trends in CR and OS may have improved over time,28
no new effective treatments emerged for adult R/R ALL over the
study period (1990–2013) and the weighting procedures used in
this study, which accounted for differences in the distribution of
various prognostic factors that varied across calendar period,
reduced this effect. Sensitivity analyses showed that when data
were restricted to sites that had data across the entire time period,
there was no difference in CR between 1990 to 1999 and 2000
onward. Thus, it could be considered that the small differences
observed in the weighted analyses by time period may be due to
improvements in treatment over time, or that they are simply due
to differences in sites contributing data over different time
periods.
Even though there is general consistency on how outcomes are
reported, heterogeneity with what was labeled as ‘complete
remission’ by the different study groups and sites is likely present
in the historical data. Some groups/sites included only those
patients who achieved bone marrow blast reduction below 5%
and full recovery of peripheral blood counts when deﬁning CR.
Other sites included patients who achieved blast reduction
without complete recovery of peripheral blood counts, which
represents the standard clinical procedure.7 It is therefore very
likely that CR rates in the historical comparator group include
patients with CRh. This study relied on the customary reporting of
CR by each participating group or site for comparison with CR/CRh
and CR estimates in the blinatumomab clinical trial data.
The results of the weighted analysis reﬂect the distribution of
patients in the blinatumomab trial, and therefore may not be fully
generalizable to studies of other novel therapies in ALL.29,30
Nevertheless, they reveal the poor prognosis of a subgroup of
patients with R/R ALL, highlight the value of accumulating
Table 4. Propensity score analysis of historical data set and blinatumomab clinical trial data: CR and overall survivala
End point Statistic Historical data set Blinatumomab trial (MT103-211)
CR/CRh rate Predicted rate (95% CI) 26.7% (23.4–30.3%) 49.3% (33.4–65.3%)
Overall survival 6-month survival rate (95% CI) 33.4% (31.0–36.1%) 57.6% (54.9–60.4%)
Overall survival 12-month survival rate (95% CI) 17.2% (15.3–19.4%) 39.0% (36.0–42.2%)
aThe propensity scores estimates vary slightly compared with weighted analysis and blinatumomab clinical trial due to adjustments made with propensity
score modeling. In the weighted analyses, blinatumomab results are not modiﬁed and the historical data are weighted to match the distribution of the
blinatumomab trial. In the propensity score analyses, both results are modiﬁed to match the distribution of a ‘pseudopopulation’ in between the
blinatumomab and historical control data set.
Figure 2. Comparison of complete response and overall survival
between blinatumomab clinical trial patients and historical patients.
Outcomes were analyzed using both the IPTW and sIPTW
approaches: Odds ratio (OR) for achieving a CR/CRh (blinatumomab
patients) or CR (historical patients) and hazard ratio (HR) for overall
survival.
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historical clinical data for assessing new therapies for this rare, serious
illness, and emphasize the need for continued support of multicentre
studies, disease registries and collaborative research efforts.
In conclusion, appropriate analytical methods are necessary to
address potential biases when comparing historical data with
those from clinical trials. By compiling the largest available data
set of adult patients with Ph-negative B-precursor R/R ALL, we
were able to use two analytical approaches in evaluating the
efﬁcacy of blinatumomab vs current treatments. The clinical
beneﬁt of blinatumomab in this population will be further
evaluated in a conﬁrmatory phase 3 randomized study.31
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